Ireland
--:--IST
Latest
Clinical Trials in Denmark / NCT07271771
Recruiting Phase 4

The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity

NCT07271771 · tracked via the Priya Life Science Denmark tracker
Phase
Phase 4
Started
2024-05-21
Last updated
2025-12-15

Condition(s) studied

Osteoporosis

Investigational drug(s) / intervention(s)

Denosumab →Saline (0.9% NaCl)

Denosumab: Denosumab 60 mg

Saline (0.9% NaCl): Placebo

Study summary

Randomized, placebo controlled prospective trial evaluating the effect of denosumab on insulin sensitivity and muscle strength.

Eligibility

Sex
FEMALE
Min age
40 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Postmenopausal women (postmenopausal for at least two years) * Age ≥ 40 years * BMD T-score ≥ -2.0 (lumbar spine, total hip or femoral neck) * At least 2 lumbar vertebrae that can be evaluated by dual-energy x-ray absorptiometry (DXA) * Diabetes Mellitus type 2 * Treatment with metformin as monotherapy Exclusion Criteria: * Treatment for osteoporosis at any time * Other antidiabetic medication than metformin * Low-energy vertebral fractures at any time * Low-energy hip fracture at any time * Ongoing treatment with systemic glucocorticoids * Metabolic bone disease (for example osteogenesis imperfecta, Paget's disease of bone, hyperparathyroidism) * Treatment affecting bone, calcium metabolism or muscle * Active cancer within the last 5 years with the exception of basal cell skin cancer * Estimated glomerular filtration rate (eGFR) ≤ 35 mL/min * Unable to read and understand Danish * Immobility

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Aarhus University Hospital Aarhus Denmark Recruiting

More Aarhus University Hospital trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07271771 on ClinicalTrials.gov ↗ ← All trials in Denmark